Jain Rajesh, Bhavatharini Natrajan, Saravanan Thangavel, Seshiah Veeraswamy, Jain Nishchal
Medicine, Jain Hospital and Research Center Pvt Ltd, Kanpur, IND.
Diabetology, SRC Diabetes Care Center, Erode, IND.
Cureus. 2022 Dec 15;14(12):e32573. doi: 10.7759/cureus.32573. eCollection 2022 Dec.
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.
主要试验，如EMPA-REG OUTCOME、CANVAS和CREDENCE试验，显示了钠-葡萄糖转运蛋白2（SGLT2）抑制剂对肾脏和心血管的益处。SGLT2抑制剂恩格列净、达格列净和卡格列净未显示出明显的不良肾脏影响。然而，在我们的研究中，临床和病理证据证实，在印度被批准用于治疗糖尿病的一种SGLT2抑制剂雷莫格列净治疗的2型糖尿病患者似乎会导致急性肾小管坏死。我们研究中的两个关键发现包括hs-CRP持续升高以及病理学家的活检报告排除了其他病因。因此，我们需要大规模的心血管-肾脏结局试验来确定雷莫格列净在未来研究中的安全性。
